AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients ...

It is estimated that these processes will make ENHERTU available to gastric cancer patients close to two years faster than traditional reimbursement pathways which would have required the ...

"As early participants in these innovative drug reimbursement processes, AstraZeneca and Daiichi Sankyo are pleased to accelerate access to innovative treatments for Canadian patients, particularly in ...

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...

AstraZeneca and Daiichi Sankyo are preparing regulatory filings that could make their HER2-directed antibody-drug conjugate (ADC) Enhertu an option for previously untreated breast cancer for the ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

WHILE DRIVING TO THE TERMINAL, THE AIRPORT IS UNVEILING THIS NEW LOGO, WHICH WILL BE SHOWN ON THE NORTH SIDE OF ITS BRAND NEW PARKING GARAGE. THE GARAGE WILL ADD 1100 NEW ON SITE PARKING SPACES.

WILMINGTON, DE — Positive results from the DESTINY-Breast11 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), when followed by paclitaxel, trastuzumab, and pertuzumab ...

Arizona is bringing back its iconic 'cactus' logo to the McKale Center floor, and asking fans exactly how to do so. The school produced four images of what the court could look like, all of which ...

On the bright side, Paramount has shared a brand-new logo for the film that you can see below. It puts The Legend of Aang: The Last Airbender’s release date back nearly nine months later than ...

One of these studies is looking at ELVN-002 in combination with AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu as a treatment for HER2-positive breast cancer. The other study ...